Subsidiary Signs Exclusive Licensing Agreement for GenSci098 Injection Project
December 17, 2025
Source: drugdu
33
According to the announcement, the company's subsidiary, Shanghai Saizeng Medical Technology Co., Ltd. (hereinafter referred to as "Saizeng Medical"), recently signed an exclusive licensing agreement with Yarrow Bioscience, Inc. for the GenSci098 injection project. Under the agreement, Saizeng Medical expects to receive an upfront payment of US$120 million and near-term development milestone payments (including a non-refundable and non-deductible upfront payment of US$70 million and subsequent near-term development milestone payments of US$50 million), and will be eligible for milestone payments related to specific research, regulatory, and commercialization. Saizeng Medical will be entitled to receive up to US$1.365 billion in milestone payments for this exclusive license, and will also be entitled to royalties exceeding 10% of net sales after the product's launch.
https://finance.eastmoney.com/a/202512153591987252.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Kangfeng Biotechnology’s Anti-Gastroesophageal Reflux System Receives Approval from the Drug Administration December 17, 2025
- Cell Metabolism | Efficacy of Akkermansia muciniphila Supplementation in Overweight/Obese Patients with Type 2 Diabetes December 17, 2025
- Major Breakthrough! China’s First Injectable Silk Fibroin Gel Enters Clinical Trials December 17, 2025
- Can AOC become the “next stop” for oligonucleotide therapy? December 17, 2025
- A global first! Two domestically developed innovative medical devices have been approved for market launch December 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
